Pharma BD Deal Intelligence
Millennium gave Takeda a real, durable oncology franchise (Velcade, then Ninlaro) and a lasting Cambridge R&D hub — but Ninlaro never came close to the "bigger than Velcade" $3B promise, and both franchise pillars have since eroded.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Takeda is paying a 53% premium and topping every analyst 12-month target on Millennium, with one analyst noting 'there have been higher premiums paid for…
Cambridge-based Millennium becomes Takeda's US oncology hub, retaining its name and Cambridge HQ — viewed locally as a positive outcome preserving the…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals, Inc. for $8.8 billion through an all-cash tender offer of $25.00 per share, a premium of roughly 53%. The deal gave Takeda the multiple-myeloma proteasome inhibitor Velcade (bortezomib) and established a Cambridge, Massachusetts-based U.S. oncology hub—Millennium retained its name and headquarters—adding oncology scale ahead of the patent cliff on Takeda's diabetes drug Actos. Then the largest overseas acquisition by a Japanese drugmaker, the transaction closed on May 14, 2008.
Millennium gave Takeda a real, durable oncology franchise (Velcade, then Ninlaro) and a lasting Cambridge R&D hub — but Ninlaro never came close to the "bigger than Velcade" $3B promise, and both franchise pillars have since eroded.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals (this deal) | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
| Takeda Pharmaceutical Company Ltd. / Insilico Medicine Inc. | 2026 | $600M | 54 |